

**From:** [REDACTED] <[REDACTED]@incisivehealth.com>  
**Sent:** lundi 31 mai 2021 17:14  
**To:** DELSAUX Pierre (SANTE)  
**Cc:** [REDACTED] (SANTE); [REDACTED] (SANTE);  
[REDACTED] AlloVir;  
**Subject:** COVID-19 therapeutics strategy - request for further information

Dear Mr Delsaux

We are contacting you on behalf of AlloVir, a clinical stage biopharmaceutical company developing novel Virus Specific T-cell therapies to treat or prevent life-threatening viral infections in high-risk patients. We are reaching out to you in the context of the Commission's recent COVID-19 therapeutics strategy announcement. AlloVir has a T-cell therapy for the treatment of High-Risk Patients with COVID-19 that received FDA clearance to start clinical trials in September 2020.

We have understood from Mr John Ryan's intervention in the European Parliament's ENVI Committee on 26 May, that the Commission will be reviewing candidate therapeutics and shortlisting ten by the end of June. AlloVir would be interested in understanding what the formal process to enter this is and how AlloVir should approach the Commission and the EMA.

We look forward to your response and please feel free to contact us should you have any questions.

Best wishes

[REDACTED]

[REDACTED]

M +32 [REDACTED]  
E [REDACTED]@incisivehealth.com  
[www.incisivehealth.com](http://www.incisivehealth.com)



**make it matter.**

Part of UDG Healthcare plc

Incisive Health, Avenue Louise 54, 1050 Brussels

Registered company number: 08433190  
Registered address: Ashfield House, Resolution Road, Ashby-De-La-Zouch, LE65 1HW, United Kingdom  
VAT number: 166370500

[Transparency register ID number 786297415977-28](#)

**Member of EPACA**

**Incisive Health and the cross device are registered trademarks in the UK**